These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22460964)

  • 21. Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3.
    Barreiro P; Martín-Carbonero L; Núñez M; Rivas P; Morente A; Simarro N; Labarga P; González-Lahoz J; Soriano V
    Clin Infect Dis; 2006 Apr; 42(7):1032-9. PubMed ID: 16511772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver biopsy findings for HIV-infected patients with chronic hepatitis C and persistently normal levels of alanine aminotransferase.
    Sánchez-Conde M; Berenguer J; Miralles P; Alvarez F; Carlos Lopez J; Cosin J; Pilar C; Ramirez M; Gutierrez I; Alvarez E
    Clin Infect Dis; 2006 Sep; 43(5):640-4. PubMed ID: 16886160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients.
    Hull MW; Rollet K; Moodie EE; Walmsley S; Cox J; Potter M; Cooper C; Pick N; Saeed S; Klein MB;
    AIDS; 2012 Sep; 26(14):1789-94. PubMed ID: 22739388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The risk of infections in HIV-HCV coinfected patients during antiviral therapy with pegIFN+RBV.
    Payer BA; Reiberger T; Breitenecker F; Aichelburg MC; Schuster C; Heil PM; Scherzer TM; Ferenci P; Rieger A; Peck-Radosavljevic M;
    J Infect; 2012 Aug; 65(2):142-9. PubMed ID: 22410384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
    Castagna A; Galli L; Torti C; D'Arminio Monforte A; Mussini C; Antinori A; Cozzi-Lepri A; Ladisa N; De Luca A; Seminari E; Gianotti N; Lazzarin A
    Antivir Ther; 2010; 15(2):165-75. PubMed ID: 20386071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preservation of immune function and anti-hepatitis C virus (HCV) immune responses after liver transplantation in HIV-HCV coinfected patients (ANRS-HC08 "THEVIC" trial).
    Samri A; Roque-Afonso AM; Beran O; Tateo M; Teicher E; Feray C; Sebagh M; Guettier C; Dussaix E; Vittecoq D; Samuel D; Autran B; Duclos-Vallée JC
    J Hepatol; 2009 Dec; 51(6):1000-9. PubMed ID: 19833404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis.
    d'Arminio Monforte A; Cozzi-Lepri A; Castagna A; Antinori A; De Luca A; Mussini C; Caputo SL; Arlotti M; Magnani G; Pellizzer G; Maggiolo F; Puoti M;
    Clin Infect Dis; 2009 Aug; 49(4):612-22. PubMed ID: 19591597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection.
    Martin-Carbonero L; de Ledinghen V; Moreno A; Maida I; Foucher J; Barreiro P; Romero M; Satta G; Garcia-Samaniego J; Gonzalez-Lahoz J; Soriano V
    J Viral Hepat; 2009 Nov; 16(11):790-5. PubMed ID: 19413693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
    Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concentrations of soluble Fas and soluble Fas ligand as indicators of programmed cell death among patients coinfected with Human Immunodeficiency Virus and Hepatitis C Virus.
    Lapinski TW; Jaroszewicz J; Wiercinska-Drapalo A
    Viral Immunol; 2006; 19(3):570-5. PubMed ID: 16987075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.
    Torti C; Prosperi M; Motta D; Digiambenedetto S; Maggiolo F; Paraninfo G; Ripamonti D; Cologni G; Fabbiani M; Caputo SL; Sighinolfi L; Ladisa N; El-Hamad I; Quiros-Roldan E; Frank I
    Clin Microbiol Infect; 2012 May; 18(5):449-58. PubMed ID: 21919996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002.
    Schiavini M; Angeli E; Mainini A; Zerbi P; Duca PG; Gubertini G; Vago L; Fociani P; Giorgi R; Cargnel A
    HIV Med; 2006 Jul; 7(5):331-7. PubMed ID: 16945079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort.
    Loko MA; Castera L; Dabis F; Le Bail B; Winnock M; Coureau G; Bioulac-Sage P; de Ledinghen V; Neau D;
    Am J Gastroenterol; 2008 Aug; 103(8):1973-80. PubMed ID: 18796094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hepatitis and posthepatic cirrhosis in AIDS].
    Bierhoff E; Fischer HP; Pfeifer U; Rockstroh J; Spengler U
    Verh Dtsch Ges Pathol; 1995; 79():249-53. PubMed ID: 8600688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events.
    Stebbing J; Waters L; Mandalia S; Bower M; Nelson M; Gazzard B
    Clin Infect Dis; 2005 Sep; 41(6):906-11. PubMed ID: 16107994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients.
    Pineda JA; González J; Ortega E; Tural C; Macías J; Griffa L; Burgos A;
    J Viral Hepat; 2010 Oct; 17(10):714-9. PubMed ID: 20002560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma.
    Clifford GM; Rickenbach M; Polesel J; Dal Maso L; Steffen I; Ledergerber B; Rauch A; Probst-Hensch NM; Bouchardy C; Levi F; Franceschi S;
    AIDS; 2008 Oct; 22(16):2135-41. PubMed ID: 18832877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Responder Interferon λ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection.
    Moqueet N; Cooper C; Gill J; Hull M; Platt RW; Klein MB;
    J Infect Dis; 2016 Jul; 214(1):80-6. PubMed ID: 26984148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.